Edition:
United States

Recro Pharma Inc (REPH.OQ)

REPH.OQ on NASDAQ Stock Exchange Capital Market

9.77USD
15 Dec 2017
Change (% chg)

$0.20 (+2.09%)
Prev Close
$9.57
Open
$9.57
Day's High
$9.79
Day's Low
$9.51
Volume
92,084
Avg. Vol
22,150
52-wk High
$10.55
52-wk Low
$5.85

Latest Key Developments (Source: Significant Developments)

Recro Pharma secures $100 million credit facility
Monday, 20 Nov 2017 07:00am EST 

Nov 20 (Reuters) - Recro Pharma Inc :Recro Pharma Inc secures $100 million credit facility.Recro Pharma Inc - ‍has secured a $100 million credit facility from funds managed by Athyrium Capital Management, LP​.Recro Pharma Inc - ‍proceeds from facility to refinance Recro's outstanding debt, pay $45 million milestone to alkermes upon approval of iv meloxicam 30mg by FDA​.  Full Article

Recro Pharma reports Q3 revenue $17.1 million
Thursday, 9 Nov 2017 07:00am EST 

Nov 9 (Reuters) - Recro Pharma Inc :Recro Pharma reports third quarter 2017 financial results.Q3 revenue $17.1 million versus I/B/E/S view $13.7 million.Recro Pharma Inc - ‍Raising its guidance for 2017 revenue from a range of $60-$63 million to $65 million​.Recro Pharma Inc qtrly ‍revenues were $17.1 million versus $17.0 million​.Recro Pharma Inc - ‍As of September 30, 2017, Recro had cash, cash equivalents and short-term investments of $41.3 million​.  Full Article

RECRO PHARMA ANNOUNCES PDUFA DATE OF MAY 26, 2018 FOR IV MELOXICAM 30MG
Thursday, 5 Oct 2017 07:00am EDT 

Oct 5 (Reuters) - Recro Pharma Inc ::RECRO PHARMA ANNOUNCES PDUFA DATE FOR IV MELOXICAM 30MG.RECRO PHARMA - U.S. FDA HAS SET A PDUFA DATE OF MAY 26, 2018 FOR ITS DECISION ON NEW DRUG APPLICATION (NDA) FOR INTRAVENOUS (IV) MELOXICAM 30MG.  Full Article

Recro Pharma announces FDA acceptance for review of new drug application for IV Meloxicam 30mg
Thursday, 28 Sep 2017 07:00am EDT 

Sept 28 (Reuters) - Recro Pharma Inc :Recro Pharma announces FDA acceptance for review of new drug application for IV Meloxicam 30mg.  Full Article

Recro Pharma quarterly ‍loss per share $0.48
Thursday, 10 Aug 2017 07:00am EDT 

Aug 10 (Reuters) - Recro Pharma Inc :Recro Pharma reports second quarter 2017 financial results.Q2 revenue $16.9 million versus i/b/e/s view $14.6 million.Qtrly ‍loss per share $0.48; Co is raising its guidance for 2017 revenue from a range of $55-$60 million to $60-$63 million​.  Full Article

Recro Pharma acquires Novel Neuromuscular blocking agents
Wednesday, 5 Jul 2017 08:00am EDT 

July 5 (Reuters) - Recro Pharma Inc :Recro Pharma acquires Novel Neuromuscular blocking agents.Says ‍under terms of agreement, Recro Pharma will pay Cornell a six figure initial up-front fee​.Recro Pharma Inc - under terms of agreement, Recro Pharma will pay Cornell a six figure initial up-front fee.Recro Pharma - ‍cornell entitled to receive additional milestone payments in millions per each acquired candidate upon achievement of certain U.S., EU regulatory approval.  Full Article

Recro Pharma files for mixed shelf‍​ of up to $100 mln - SEC Filing ‍​
Monday, 5 Jun 2017 07:58am EDT 

June 5 (Reuters) - Recro Pharma Inc :Recro pharma files for mixed shelf‍​ of up to $100 million - sec filing ‍​.  Full Article

Recro Pharma reports Q1 loss per share of $0.42
Thursday, 11 May 2017 07:00am EDT 

May 11 (Reuters) - Recro Pharma Inc :Recro Pharma reports first quarter 2017 financial results.Q1 loss per share $0.42.Sees FY 2017 revenue $55 million to $60 million.Q1 revenue $18.7 million versus I/B/E/S view $15.2 million.Q1 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S.On track to file NDA with U.S. FDA for IV Meloxicam during early Q3 2017.Reiterates its expectation that it will generate revenue in range of $55-$60 million in 2017.  Full Article

Recro Pharma reports year end 2016 financial results
Monday, 6 Mar 2017 04:05pm EST 

Recro Pharma Inc : Recro Pharma reports year end 2016 financial results .Sees FY 2017 revenue $55 million to $60 million.  Full Article

Recro Pharma announces proposed public offering of common stock
Thursday, 8 Dec 2016 09:02am EST 

Recro Pharma Inc : Recro Pharma Inc - intends to use net proceeds of proposed offering to fund NDA filing for IV Meloxicam .Recro Pharma announces proposed public offering of common stock.  Full Article

BRIEF-Recro Pharma secures $100 million credit facility

* Recro Pharma Inc - ‍has secured a $100 million credit facility from funds managed by Athyrium Capital Management, LP​